ArticleRenal failure2025
Effects of Shenkang for chronic kidney disease: a propensity score matched with network pharmacology analysis.
Article in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Shenkang (SK) is a widely used formula for treating chronic kidney disease (CKD) since the 1990s. However, the associations of SK use with the long-term outcome among CKD patients have not been validated in real-world study. This single-center retrospective study included outpatients with CKD from 1 January 2013, to 31 December 2023. Patients who received SK were compared with control group after propensity score matching. A total of 2,463 patients met the inclusion criteria, with 546 matched pairs. The SK group had a significantly lower risk of end-stage renal disease (adjusted hazard ratios = 0.83, 95% confidence interval: 0.70-0.98;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.